Lipoprotein(a) Foundation Expands Global Scientific Advisory Board

Advisory Board to Be Actively Involved in the First-Ever Prospective Patient Registry to Study Lp(a) in the U.S. with Recent Grant from NORD in Conjunction with FDA

SAN CARLOS, Calif.--()--The Lipoprotein(a) Foundation announced today that it has expanded its global Scientific Advisory Board (SAB) to 27 members. The Advisory Board, comprised of the world’s leading experts on Lipoprotein(a), a highly prevalent, independent, genetic risk factor for early cardiovascular disease, provides support to the Foundation’s mission of saving lives by increasing awareness, advocating for routine testing, and supporting research that will lead to a specific treatment for elevated Lipoprotein(a).

The Lipoprotein(a) Foundation Scientific Advisory Board includes the following third party scientists, lipidologists, cardiologists and healthcare professionals:

  • Benoit Arsenault, Ph.D., Universite Laval
  • Christie M. Ballantyne, M.D., Baylor College of Medicine
  • W. Virgil Brown, M.D., Emory University
  • John Chapman, Ph.D., DSc, Pitie-Salpetriere Hospital
  • Robert Clarke, M.D., Oxford University
  • Tom Dayspring, M.D., True Health Diagnostics
  • Keith Ferdinand, M.D., Tulane University,
  • Steve Foley, M.D., Comprehensive Women’s Care
  • Henry Ginsberg, M.D., Columbia College of Physicians and Surgeons
  • Jemma Hopewell, Ph.D., University of Oxford
  • Terry Jacobson, M.D., Emory University
  • Marlys Koschinsky, Ph.D., Robarts Research Institute, Western University
  • Florian Kronenberg, M.D., Medical University of Innsbruck
  • Joe McConnell, Ph.D., Salveo Diagnostics
  • Catherine J. McNeal, M.D., Ph.D., Baylor Scott & White Health
  • Michele Meitus Snyder, M.D., Children’s National Medical Center
  • Patrick M. Moriarty, M.D., University of Kansas Hospital
  • Pamela Morris, M.D., Medical University of South Carolina
  • Borge Nordestgaard, M.D., University of Copenhagen
  • Alan Remaley, M.D., Ph.D., National Heart, Lung, Blood
  • Raul Santos, M.D., Ph.D., University of Sao Paulo
  • Suzanne Shugg, N.P., NJ Cardiology Associates
  • Sam Tsimikas, M.D., University of California
  • Marina Vernalis, D.O., Walter Reed National Military Medical Center
  • Annabelle Santos Volgman, M.D., Rush College of Medicine
  • Robert Wild, M.D., Ph.D., University of Oklahoma
  • Joseph Witztum, M.D., University of California

In breaking news, the latest issue of The Lancet includes a paper from Advisory Board member Børge G. Nordestgaard, MD, DMSc, of the University of Copenhagen, titled “High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.” The results suggest that high lipoprotein(a) concentrations and corresponding LPA risk genotypes represent novel risk factors for clinical familial hypercholesterolaemia. The authors conclude that all individuals with familial hypercholesterolaemia should have their lipoprotein(a) measured in order to identify those with the highest concentrations, and as a result, the highest risk of myocardial infarction.

The Foundation recently announced that it has received a grant from the National Organization of Orphan Diseases (NORD) in conjunction with the U.S. Food & Drug Administration (FDA), to create the first prospective patient registry to study Lp(a) in the United States by collecting Lp(a) patient histories for research purposes. Members of the Advisory Board will be actively involved in data collection and analysis for the patient registry.

“The mission of the Lipoprotein(a) Foundation is to empower patients and prevent cardiovascular events due to high Lipoprotein(a) through proper testing and diagnosis. Patients and their families look to the Foundation for resources to help them live with elevated Lp(a) and it is critical that the information we provide is as timely and accurate as possible. We are grateful for the extraordinary expertise and support that we receive from our Scientific Advisory Board, without which we could not achieve these goals. We look forward to collaborating with our new members to continue raising awareness and working towards the development of specific treatments for high Lipoprotein(a),” said Sandra Revill Tremulis, founder of Lipoprotein(a) Foundation.

Tremulis will present at the International Lp(a) Satellite Meeting, May 27-28, 2016 in Innsbruck, Austria, as part of a Symposium titled, “A patient centered approach targeting Lp(a) in lipid management.” Tremulis has also been invited to participate in panel discussion on Clinical Aspects of Lp(a) moderated by meeting chair Florian Kronenberg, MD. The International Lp(a) Symposium is designed to bring together the leading experts in Lp(a) research to share the most recent results and promote knowledge of this important risk factor for atherosclerosis.

A number of Advisory Board members will also be presenting at the upcoming National Lipid Association 2016 Scientific Sessions (NLA), May 19-22 in New Orleans. Highlights include: “Lipoprotein(a) as a Cause of Cardiovascular Disease,” by Dr. Nordestgaard, and “Drugs in Development to Treat Lp(a): Risk Reduction vs. Lowering a number - What can we expect?” by Christie M. Ballantyne, MD, FNLA, of the Baylor College of Medicine.

A study recently published in the Journal of the American College of Cardiology (JACC) shows that the current cholesterol guidelines miss 8% of people who have a cardiovascular event whose only risk factor is high Lp(a).1 One in 5 people globally have inherited high Lp(a) – approximately 63 million in the U.S.4 and Lp(a) is a highly prevalent, independent, genetic risk factor for coronary heart disease and aortic stenosis.2 Lp(a) concentrations can be measured by a simple blood test, but it is not included in most standard lipid panel tests that check cholesterol levels. 1 The Lipoprotein(a) Foundation recently issued an Infographic to raise awareness that a simple blood test could be the first step in preventing up to 120,000 cardiovascular events every year.

About The Lipoprotein(a) Foundation

Because approximately 63 million Americans have high Lipoprotein(a) and are at risk of premature cardiovascular disease, the vision for the foundation is: To live in a world where high Lipoprotein(a) is routinely diagnosed, treated and family screened. The mission is to prevent cardiovascular events due to high Lipoprotein(a) by diagnosing this inherited risk for cardiovascular disease; educating and empowering patients and saving lives. Our goal is to save lives by increasing awareness, advocating for routine testing, and supporting research that will lead to a specific treatment for elevated Lipoprotein(a). Based in San Carlos, California, the Lipoprotein(a) Foundation is a patient-founded, 501(c)3 non-profit organization. For more information go to:

1 Mortensen M, MD, PHD, Afzal S, MD, PHD et al. Primary Prevention with Statins. ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. Guide Statin Therapy. JACC.

2 CARDIoGRAMplusC4D Consortium, Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013 Jan;45(1):25-33

3 Thanassoulis G. et al. Genetic Associations with Valvular calcification and aortic stenosis. N Engl J Med. 2013 Feb 7;368(6):503-12. doi: 10.1056/NEJMoa1109034

4 Nordestgaard F., Chapman J, et al. Lipoprotein(a) as a cardiovascular risk factor current status. European Heart J. 2010;31,2844-2853

5 CDC reference:


Lipoprotein(a) Foundation
Chris K. Joseph, 510-435-4031

Release Summary

The Lipoprotein(a) Foundation has expanded its global Scientific Advisory Board (SAB) and includes the world’s leading experts on Lp(a), a prevalent, independent, genetic risk factor for CV disease


Lipoprotein(a) Foundation
Chris K. Joseph, 510-435-4031